A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1CompletedNCT02219724

Genentech, Inc.174 enrolled

Overview

This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of MOXR0916 administered intravenously in participants with locally advanced or metastatic solid tumors that have progressed after all available standard therapy or for which standard therapy has proven to be ineffective or intolerable, or is considered inappropriate. This study will consist of a screening period, an initial treatment period, a re-treatment period (for participants who discontinue MOXR0916 after demonstration of prolonged clinical benefit), and a post-treatment follow-up period. Participants will be enrolled in two stages: a dose-escalation stage and an expansion stage. The planned duration of the study is approximately 3 years.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

174

Conditions

Neoplasms

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologic documentation of locally advanced, recurrent or metastatic incurable solid malignancy that has progressed after all available standard therapy or for which standard therapy has proven to be ineffective or intolerable, or is considered inappropriate * Confirmed availability of representative tumor specimens in paraffin blocks/unstained slides * Measurable disease per RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate hematologic and end organ function * For female participants of childbearing potential, agreement to use highly effective form(s) of contraception and to continue its use for 6 months after the last dose of MOXR0916 Exclusion Criteria: * Any anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment (hormonal therapy with gonadotropin-releasing hormone agonists or antagonists for prostate cancer and palliative radiotherapy greater than (\>) 2 weeks prior to Cycle 1, Day 1 are allowed) * Eligibility based on prior treatment with immunomodulatory agents depends on the mechanistic class of the drug and the cohort for which the participant is being considered * Adverse events from prior anti-cancer therapy that have not resolved to Grade less than or equal to (\</=) 1 except for alopecia or endocrinopathy managed with replacement therapy * Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases * Leptomeningeal disease * Malignancies other than disease under study within 5 years * History of autoimmune disease * History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted * Positive test for human immunodeficiency virus infection * Active hepatitis B or active hepatitis C * Severe infections within 4 weeks or signs or symptoms of infection within 2 weeks prior to Cycle 1 * Prior allogeneic bone marrow transplantation or prior solid organ transplantation * Significant cardiovascular disease * Known clinically significant liver disease

Locations (31)

HonorHealth Research Institute - Bisgrove

Scottsdale, Arizona, United States

University of Colorado

Aurora, Colorado, United States

Yale School of Medicine

New Haven, Connecticut, United States

Georgetown University Medical Center Lombardi Cancer Center

Washington D.C., District of Columbia, United States

University Of Chicago Medical Center; Section Of Hematology/Oncology

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Percentage of Participants With Dose Limiting Toxicities (DLTs)

Time frame: Day 1 Up to Day 21 or 42

Percentage of Participants With Adverse Events (AEs) by Severity as Graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0)

Time frame: Baseline up to 90 days after the last dose of study treatment, or until the initiation of another systemic anti-cancer therapy, whichever occurs first (approximately up to 3 years)

Secondary Outcomes

Maximum Tolerated Dose (MTD) of MOXR0916

Time frame: Baseline up to 21 to 42 days

Recommended Phase II Dose of MOXR0916

Time frame: Baseline up to 21 to 42 days

Percentage of Participants With Anti-MOXR0916 Antibodies

Time frame: Pre-dose (Hour [Hr] 0) on Day (D) 1 of Cycles (Cy) 1,2,3,4,8,12,16, & then every 8 Cy up to treatment discontinuation visit (TDV) (up to approximately 3 years) (1 Cy=21 days), thereafter every 30 days for up to 120 days after treatment discontinuation

Number of Cycles of MOXR0916 Treatment Received

Time frame: Baseline up to approximately 3 years

Mean MOXR0916 Dose Administered During Study

Time frame: Baseline up to approximately 3 years

Area Under the Serum Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-last]) of MOXR0916

Time frame: Cy1 (1Cy=21 days): Predose (Hr0), 0.5,24,72 hrs postinfusion (infusion duration=1.5 hrs) on D1; on D8, 15; Cy2-7: Hr0, 0.5 hrs postinfusion on D1; Cy8,12,16, then every 8 Cy up to TDV (approx. 3 years): Hr0 on D1; every 30 days after TDV up to 120 days

Maximum Observed Serum Concentration (Cmax) of MOXR0916

Minimum Observed Serum Concentration (Cmin) of MOXR0916

Serum Clearance (CL/F) of MOXR0916

Apparent Volume of Distribution at Steady State (Vss) of MOXR0916

Percentage of Participants With Objective Response as Determined Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

Time frame: Baseline, end of Cycles 2, 4, 6, 8, and every 4 cycles thereafter (cycle length=21 days) until disease progression, death, another anti-cancer therapy initiation, loss to follow-up, consent withdrawal, or study termination (approximately up to 3 years)

Duration of Objective Response (DOR) as Determined Using RECIST v1.1

Progression-free Survival (PFS) as Determined Using RECIST v1.1

Percentage of Participants With Objective Response as Determined Using Modified RECIST

DOR as Determined Using Modified RECIST

PFS as Determined Using Modified RECIST

Overall Survival (OS)

Time frame: Baseline until death, loss to follow-up, withdrawal of consent, or study termination by the Sponsor (approximately up to 3 years)